The copper belongs in the GHK-Cu explanation.
GHK-Cu has a small name with two important parts. I keep both in view, then check whether we're talking about skin, cells or an injection.
Three amino acids, plus copper.
GHK is a chain of three amino acids. GHK-Cu is that chain bound to copper. The Cu is doing useful work in the name, so I don't leave it out.
The three amino acids are glycine, histidine and lysine. You may also see GHK-Cu called Copper Tripeptide-1 in skincare. The GHK review explains the naming.
In one cell experiment, GHK-Cu increased collagen production. Collagen is a protein that gives skin structure. That's a reason researchers became interested, but cells in a dish can't show what a cream or injection will do for you.
When a claim jumps straight from collagen to better-looking skin, I look for the missing step: a study that measured that change in people.
Skin research stays about skin.
Topical means applied to the skin. Even within that setting, getting an ingredient through skin and showing a useful effect are two separate questions.
In a study of removed human skin, researchers measured copper passing through and staying in skin layers. They measured copper, not the whole peptide, and weren't testing a benefit in living people.
A review of topical GHK describes limited clinical evidence and problems getting the ingredient through skin. I read those limits alongside the interesting cell findings.
People in skincare communities report redness, itching or dryness. Those are anecdotes, not clinical evidence. Small studies reporting few problems can't establish safety for everyone, and skin findings don't settle injection safety.
Access depends on the route too.
FDA treats injected and non-injected GHK-Cu differently. That distinction belongs beside any discussion of prescriptions, rather than leaving you to guess which form is meant.
FDA's 503A list, updated May 14, 2026, puts non-injectable GHK-Cu in Category 1, its group under evaluation. Under this interim policy, FDA says it plans to hold off on enforcement if the compounder meets its conditions. That isn't approval or a guarantee that a preparation is lawful.
On FDA's safety page, current April 22, 2026, injectable GHK-Cu is nominated but withdrawn. Taking back a request isn't clearance. FDA still flags possible immune reactions from clumping or impurities and limited human safety data.
Promise Peptides offers GHK-Cu prescription care (mypromise.com). A licensed U.S. provider reviews your situation and decides whether to prescribe; the provider can decline care. Care is limited to the United States, and compounded medicines are not FDA-approved. Access still leaves questions about the preparation, route and evidence.